Remove Clinical Trials Remove Data Remove Media Remove Medicine
article thumbnail

Press Release: Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Cannabis Law Report

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Matthew Johnson.

article thumbnail

ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)

Cannabis Law Report

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. Clinical Trials.gov Identifier: NCT03787628 ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ANANDA Scientific and David Geffen School of Medicine UCLA Announce Clinical Trial Utilizing Liquid StructureTM Cannabidiol (CBD) for the Treatment of Opioid Use Disorder (OUD)

Cannabis Law Report

This trial is being led by principal investigators Edythe London, Ph.D., Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal Pharmacology at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D.,

article thumbnail

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

Cannabis Law Report

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

article thumbnail

Goldfinch Bio Announces Upcoming Presentations at American Society of Human Genetics (ASHG) 2021 Meeting and American Society of Nephrology’s (ASN) Kidney Week 2021

Cannabis Law Report

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We

article thumbnail

Press Release: MindMed Engages in Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

Cannabis Law Report

9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. Thu, December 9, 2021, . NEW YORK , Dec. ” About MindMed.

article thumbnail

Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Cannabis Law Report

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS